Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Description: Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Ambirix [Hepatitis A (Inactivated) & Hepatitis B (rDNA) Vaccine] is GSK's bivalent combination vaccine that protects children and adolescents against disease caused by HAV and acute and chronic infections caused by all known strains of HBV. Ambirix contains the antigenic components used in GSK's Havrix (formalin-inactivated HAV) and GSK's Engerix-B (yeast-derived recombinant HBsAg). In 2002, Ambirix was approved in the 5EU for active immunization of children and adolescents 1–15 years of age utilizing a two-dose regimen for primary vaccination.

Scope

- Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ambirix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ambirix for the UK from 2012 to 2022.
- Sales information covered for the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ambirix performance
- Obtain sales forecast for Ambirix from 2012-2022 in the UK.

Contents:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
4 Vaccination Recommendations and Coverage Rates
4.1 Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Ambirix
6.1 Overview
6.2 Immunogenicity
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Patient Populations Targeted for Vaccination
7.4.2 Vaccination Coverage Rates
7.4.3 Vaccinated Patients
7.4.4 Regulatory Approval vs. Advisory Committee Recommendation
7.4.5 General Pricing Assumptions
7.4.6 Individual Vaccine Assumptions
7.5 Physicians and Specialists Included in this Study
7.5.1 Interviews of Key Opinion Leaders (KOLs)
7.5.2 Online Survey of High-Prescribing Physicians (non-KOLs)
7.6 About the Authors
7.6.1 Analyst
7.6.2 Therapy Area Director
7.6.3 Global Head of Healthcare
7.7 About Us
7.8 Disclaimer

1.1 List of Tables
Table 1: Modes of HBV Transmission
Table 2: HBV Serological Markers and Test Interpretations
Table 3: Symptoms of HBV Infection
Table 4: HBV Vaccination Advisory Committees by Country
Table 5: HBV Immunization Recommendations by Country
Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
Table 7: Leading Vaccines for HBV, 2014
Table 8: Product Profile - Ambirix
Table 9: Immunogenicity Profile - Ambirix
Table 10: Safety Profile - Ambirix
Table 11: Ambirix SWOT Analysis, 2014
Table 12: Global Sales Forecasts ($m) for Ambirix, 2012-2022
Table 13: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
Table 14: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

1.2 List of Figures
Figure 1: HBV Structure and the Recombinant Vaccine Development Process

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2785075/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2785075/
Office Code: SC6I5R79

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Site License</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 10485</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address   | Ulster Bank,
                 27-35 Main Street,
                 Blackrock,
                 Co. Dublin,
                 Ireland. |

If you have a Marketing Code please enter it below:

Marketing Code: _______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp